Quarterly ResultMay 14, 2026, 04:33 PM
Biofrontera Q1 Revenue +17.4% to $10.08M; Operating Cash Burn Down
AI Summary
Biofrontera Inc. reported product revenues of $10.08 million for the first quarter of 2026, a 17.4% increase from $8.59 million in the prior year. The company significantly reduced its net cash outflow from operations to $0.07 million, a substantial improvement from $4.12 million in Q1 2025. Despite these operational improvements, management has raised substantial doubt about the company's ability to continue as a going concern for the next twelve months due to inadequate capital resources. The company also regained compliance with Nasdaq's minimum bid price requirement.
Key Highlights
- Product revenues increased 17.4% to $10.08 million for Q1 2026 from $8.59 million in Q1 2025.
- Net loss for Q1 2026 was $(4.75) million, compared to $(4.20) million in Q1 2025.
- Basic and diluted loss per common share improved to $(0.41) in Q1 2026 from $(0.47) in Q1 2025.
- Net cash outflows from operations significantly decreased to $(0.07) million in Q1 2026 from $(4.12) million in Q1 2025.
- Cash and cash equivalents were $6.32 million as of March 31, 2026, a slight decrease from $6.39 million at Dec 31, 2025.
- Management raised substantial doubt about the company's ability to continue as a going concern.
- Biofrontera regained compliance with Nasdaq's minimum bid price requirement.
- Total assets decreased to $24.79 million as of March 31, 2026, from $28.56 million at Dec 31, 2025.
Price Impact
More from BFRI